Brokers Issue Forecasts for Foghorn Therapeutics Inc.’s Q1 2025 Earnings (NASDAQ:FHTX)

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share estimates for Foghorn Therapeutics in a research note issued to investors on Monday, May 6th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.36) per share for the quarter. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($2.05) per share. Wedbush also issued estimates for Foghorn Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.30) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Foghorn Therapeutics in a research note on Tuesday.

Foghorn Therapeutics Stock Performance

Shares of NASDAQ FHTX opened at $5.98 on Wednesday. The company has a 50 day simple moving average of $6.41 and a two-hundred day simple moving average of $5.35. Foghorn Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $9.97. The company has a market capitalization of $254.57 million, a price-to-earnings ratio of -2.39 and a beta of 3.15.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.22. The firm had revenue of $5.77 million during the quarter, compared to the consensus estimate of $4.91 million.

Hedge Funds Weigh In On Foghorn Therapeutics

Several institutional investors have recently made changes to their positions in the business. Raymond James & Associates raised its position in shares of Foghorn Therapeutics by 45.0% during the 4th quarter. Raymond James & Associates now owns 2,068,387 shares of the company’s stock valued at $13,341,000 after purchasing an additional 642,161 shares during the period. Panagora Asset Management Inc. grew its position in Foghorn Therapeutics by 180.6% in the fourth quarter. Panagora Asset Management Inc. now owns 97,017 shares of the company’s stock worth $626,000 after acquiring an additional 62,441 shares in the last quarter. Birchview Capital LP increased its position in shares of Foghorn Therapeutics by 21.2% during the 4th quarter. Birchview Capital LP now owns 320,930 shares of the company’s stock valued at $2,070,000 after purchasing an additional 56,087 shares during the last quarter. Alta Wealth Advisors LLC purchased a new stake in shares of Foghorn Therapeutics in the fourth quarter valued at $194,000. Finally, Exchange Traded Concepts LLC lifted its stake in Foghorn Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 21,535 shares of the company’s stock worth $139,000 after purchasing an additional 5,460 shares during the last quarter. Institutional investors own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.